| Popis: |
To investigate the efficacy, prognosis and safety of decitabine combined with low-dose CAG regimen in the treatment of elderly patients with acute myeloid leukemia （AML）.The clinical data of 40 elderly patients with relapsed/refractory AML （69-85 years old） admitted to our hospital from January 2014 to August 2016 were analyzed retrospectively. 40 patients were divided into combination therapy group and CAG group according to different treatment methods. 20 patients of the combination therepy group were treated with decitabine combined with low-dose CAG （decitabine, 15 mg/mIn combination therapy group the CR was 55.00% （11/20）, OR was 85.00% （17/20）, but in the CAG group CR was 30.00% （6/20）, and OR was 50.00% （10/20）. Till to February 2018, out of 40 patients 17 survived, 20 died, and 3 failed to be followed-up. The median follow-up time was 12 （2 to 35） months; the median survival time in the comtination therapy group was 13 （2-35） months, and the 1-year OS rate was 70.00%, and the median survival time of the CAG group was 10 （2-31） months, and the 1-year OS rate was 50.00%, without staistical significance between the 2 groups （P0.05）. After treatment, the WBC and Plt counts in the combination therapy group were higher than those in the CAG group, but the Hb level was lower than that in the CAG group with statistically significant difference （P0.05）. In the combination therapy group, the incidence of lung infection, nausea and vomiting was higher than that of the CAG group （65.00% vs 25.00%, 50.00% vs 20.00%）, with statistically significant difference （P0.05）.Decitabine combined with low-dose CAG regimen is effective for the treatment of relapsed/refractory AML in the elderly. Compared with the standard CAG regimen, the long-term efficacy of this regimen is not different significantly, but its adverse reactions are increase, thus the preventive treatment should be given in time.地西他滨联合低剂量阿糖胞苷治疗老年复发/难治性急性髓系白血病患者的疗效、预后及安全性分析.探讨地西他滨联合低剂量CAG化疗方案治疗老年复发/难治性急性髓系白血病（acute myeloid leukemia，AML）患者的疗效、预后及安全性.回顾性分析本院在2014年1月至2016年8月收治的40例老年复发/难治性AML患者（69-85岁）的临床资料，根据治疗方案不同分为联合治疗组和对照组，各20例。联合治疗组采用地西他滨联合低剂量CAG方案（地西他滨，15 mg/m联合治疗组CR 55.00%（11/20），OR 85.00%（17/20）（P0.05）；CAG组CR 30.00%（6/20），OR 50.00%（10/20）。截止至2018年2月，40例患者中17例存活，20例死亡，3例失访，中位随访时间12（2-35）个月。联合治疗组中位生存时间13（2-35）个月，1年OS率为70.00%；CAG组中位生存时间10（2-31）个月，1年OS率为50.00%，差异无统计学意义（P0.05）。治疗后联合治疗组外周血WBC、Plt数高于CAG组，Hb水平低于CAG组，差异具有统计学意义（P0.05）。联合治疗组肺部感染、恶心呕吐发生率高于CAG组（65.00% vs 25.00%，50.00% vs 20.00%），差异具有统计学意义（P0.05）.地西他滨联合低剂量CAG方案治疗老年复发/难治性AML近期疗效显著，远期疗效并无差异，但不良反应增加，在临床在治疗过程中要及时给予预防性处理. |
